Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
2014 (English)In: Oncoimmunology, ISSN 2162-402X, Vol. 3, no 2, e27400Article in journal, Editorial material (Other academic) Published
Local immunotherapy resurfaces in the field of cancer as a potential way to cure localized and metastatic disease with limited toxic effects. We have recently demonstrated that local administration of agonistic CD40 antibodies can cure localized as well as disseminated bladder neoplasms. This approach reduces the circulating concentrations of antibodies that would result from systemic delivery, hence resulting in limited toxicity.
Place, publisher, year, edition, pages
2014. Vol. 3, no 2, e27400
antibody, bladder cancer, CD40, local immunotherapy
Immunology in the medical area Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-231498DOI: 10.4161/onci.27400ISI: 000339952700020OAI: oai:DiVA.org:uu-231498DiVA: diva2:744628